Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG).

被引：68
|
作者：
Balar, Arjun Vasant
Kulkarni, Girish S.
Uchio, Edward M.
Boormans, Joost
Mourey, Loic
Krieger, Laurence Eliot Miles
Singer, Eric A.
Bajorin, Dean F.
Kamat, Ashish M.
Grivas, Petros
Seo, Ho Kyung
Nishiyama, Hiroyuki
Konety, Badrinath R.
Nam, Kijoeng
Kapadia, Ekta
Frenkl, Tara L.
De Wit, Ronald
机构：
[1] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[2] Univ Toronto, UHN Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] UC Irvine Hlth, Orange, CA USA
[4] Erasmus MC, Rotterdam, Netherlands
[5] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[6] Royal North Shore Hosp, Northern Canc Inst, St Leonards, NSW, Australia
[7] Rutgers Canc Inst New Jersey, Sect Urol Oncol, New Brunswick, NJ USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Univ Washington, Seattle, WA 98195 USA
[11] Natl Canc Ctr, Goyang, South Korea
[12] Univ Tsukuba, Tsukuba, Ibaraki, Japan
[13] Univ Minnesota, Minneapolis, MN USA
[14] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.350
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
350
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Singer, E. A.
    Krieger, L.
    Grivas, P.
    Bajorin, D.
    Seo, H. K.
    Mourey, L.
    Kamat, A.
    Nishiyama, H.
    Kapadia, E.
    Nam, K.
    Frenkl, T.
    Balar, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
  • [2] Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG): Updated follow-up from KEYNOTE-057.
    De Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Krieger, Laurence Eliot Miles
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guerin (BCG)-unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Gupta, S.
    Kulkarni, G.
    Necchi, A.
    Shore, N. D.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    [J]. EUROPEAN UROLOGY, 2024, 85 : S433 - S433
  • [4] KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
    Kamat, Ashish M.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Nam, Kijoeng
    De Santis, Maria
    Dreicer, Robert
    Hahn, Noah M.
    Perini, Rodolfo F.
    Siefker-Radtke, Arlene O.
    Sonpavde, Guru
    De Wit, Ronald
    Witjes, Alfred
    Keefe, Stephen Michael
    Bajorin, Dean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
    Necchi, A.
    Shore, N. D.
    Gupta, S.
    Kulkarni, G.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    [J]. EUROPEAN UROLOGY, 2023, 83 : S748 - S748
  • [6] Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guerin (BCG) unresponsive, high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.
    Balar, Arjun Vasant
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Bajorin, Dean F.
    Roumigui, Mathieu
    Singer, Eric A.
    Krieger, Laurence Eliot Miles
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Zambon, Joao Paulo
    Kapadia, Ekta
    De Wit, Ronald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY
    Singer, Eric
    Necchi, Andrea
    Roumiguie, Mathieu
    Esen, Ahmet Adil
    Lebret, Thierry
    de Wit, Ronald
    Bajorin, Dean F.
    Krieger, Laurence E. M.
    Kandori, Shuya
    Uchio, Edward M.
    Seo, Ho Kyung
    Boormans, Joost
    Kamat, Ashish M.
    Grivas, Petros
    Nishiyama, Hiroyuki
    Baranwal, Pranshu
    Kapadia, Ekta
    Van den Sigtenhorst-Fijlstra, Margot
    Kulkarni, Girish S.
    Shore, Neal D.
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E1195 - E1195
  • [8] OUTCOMES IN PATIENTS (PTS) WITH BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK (HR) NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) WHO UNDERWENT RADICAL CYSTECTOMY (RC) FOLLOWING PEMBROLIZUMAB (PEMBRO) TREATMENT IN KEYNOTE-057 COHORT A
    Kulkarni, Girish S.
    Kamat, Ashish M.
    Uchio, Edward M.
    Roumiguie, Mathieu
    Krieger, Laurence E. M.
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    De Wit, Ronald
    Kapadia, Ekta
    Xing, Aiwen
    Fijlstra, Margot Van den Sigtenhorst
    Boormans, Joost L.
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E872 - E873
  • [9] Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
    de Wit, R.
    Kamat, A. M.
    Bellmunt, J.
    Choueiri, T. K.
    Nam, K.
    De Santis, M.
    Dreicer, R.
    Hahn, N. M.
    Perini, R.
    Siefker-Radtke, A. O.
    Sonpavde, G.
    Witjes, J. A.
    Keefe, S.
    Bajorin, D.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.
    Kamat, Ashish M.
    Shore, Neal D.
    Hahn, Noah M.
    Alanee, Shaheen Riadh
    Nishiyama, Hiroyuki
    Shariat, Shahrokh F.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Steinberg, Gary D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345